Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson’s disease and related disorders inside and outside of the brain, announced that Dr. Milton Werner, Ph.D., Chief Executive Officer of Inhibikase, will present at the Jefferies Virtual Healthcare Conference
May 25, 2021
· 1 min read